Article Text

PDF
Is surveillance of the small bowel indicated for Lynch syndrome families?
  1. G L ten Kate1,
  2. J H Kleibeuker2,
  3. F M Nagengast3,
  4. M Craanen4,
  5. A Cats5,
  6. F H Menko6,
  7. H F A Vasen1
  1. 1Dutch HNPCC-Registry, Department of Gastroenterology of the Leiden University Medical Centre Leiden, Netherlands; Department of Gastroenterology of the Leiden University Medical Centre Leiden, Netherlands
  2. 2Department of Gastroenterology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
  3. 3Department of Gastroenterology, University Medical Centre Nijmegen, Nijmegen, Netherlands
  4. 4Department of Gastroenterology, Free University Medical Centre, Amsterdam, Netherlands
  5. 5National Cancer Institute, Amsterdam, Netherlands
  6. 6Department of Clinical Genetics, Free University Medical Centre, Amsterdam, Netherlands
  1. Correspondence to:
    Hans F A Vasen
    MD, PhD, Netherlands Foundation for the Detection of Hereditary Tumours and Department of Gastroenterology, Leiden University Medical Centre, Poortgebouw Zuid, 2333 AA Leiden, Netherlands; hfavasen{at}stoet.nl

Abstract

Background: Small bowel cancer (SBC) is one of the tumours associated with Lynch syndrome (LS). To advise on screening for this tumour it is paramount to be informed about the lifetime risk. The aim of this study was to calculate the lifetime risk of SBC in LS and to identify possible risk factors.

Methods: Clinical and pathological data were collected on 1496 proven or putative carriers of a mismatch repair gene mutation from 189 families. Kaplan-Meier survival analysis was used to calculate the lifetime risk and to assess potential risk factors.

Results: 28 (1.9%) of the 1496 (putative) mutation carriers were identified with SBC. The median age at diagnosis was 52 years (range 23–69 years). The lifetime risk of developing SBC was 4.2%. There was no difference in risk between males and females (log rank: p = 0.2470), or between MLH1 and MSH2 mutation carriers (log rank: p = 0.2754). SBC was not observed in MSH6 mutation carriers (n = 203). The previous occurrence of colorectal cancer and a family history of SBC did not increase the risk significantly.

Conclusions: Approximately, one out of 25 mutation carriers will develop SBC during life. No specific risk factors were identified. The risk appeared to be too low to advise screening by means of an invasive burdensome procedure like double balloon enteroscopy. However, screening by a non-invasive procedure (videocapsule endoscopy) might be considered if future studies will show its cost effectiveness. In patients with unexplained abdominal complaints and/or unexplained iron deficiency anaemia SBC should be considered.

  • CRC, colorectal carcinomas
  • DBE, double balloon endoscopy
  • GC, gastric cancer
  • HNPCC, hereditary non-polyposis colorectal cancer
  • LS, Lynch syndrome
  • MMR, mismatch repair
  • SBC, small bowel cancer
  • VCE, video capsule endoscopy
  • hereditary nonpolyposis colorectal cancer
  • Lynch syndrome
  • small bowel cancer

Statistics from Altmetric.com

Footnotes

  • Published Online First 4 April 2007

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Digest
    Robin Spiller Emad El-Omar